EyePoint Pharmaceuticals Stock Forecast, Price & News

+0.35 (+3.68 %)
(As of 06/14/2021 11:13 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume573 shs
Average Volume289,097 shs
Market Capitalization$283.10 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive EYPT News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EyePoint Pharmaceuticals logo

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.70 out of 5 stars

Medical Sector

322nd out of 2,099 stocks

Analytical Instruments Industry

5th out of 32 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

EyePoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions

Is EyePoint Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EyePoint Pharmaceuticals stock.
View analyst ratings for EyePoint Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than EyePoint Pharmaceuticals?

Wall Street analysts have given EyePoint Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but EyePoint Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals saw a increase in short interest in May. As of May 14th, there was short interest totaling 1,230,000 shares, an increase of 116.3% from the April 29th total of 568,700 shares. Based on an average daily trading volume, of 235,900 shares, the days-to-cover ratio is currently 5.2 days. Approximately 5.9% of the shares of the company are sold short.
View EyePoint Pharmaceuticals' Short Interest

When is EyePoint Pharmaceuticals' next earnings date?

EyePoint Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for EyePoint Pharmaceuticals

How were EyePoint Pharmaceuticals' earnings last quarter?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) announced its earnings results on Wednesday, May, 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.52) by $0.02. The business had revenue of $7.32 million for the quarter, compared to analyst estimates of $8.29 million. EyePoint Pharmaceuticals had a negative net margin of 129.85% and a negative trailing twelve-month return on equity of 119.41%.
View EyePoint Pharmaceuticals' earnings history

How has EyePoint Pharmaceuticals' stock been impacted by Coronavirus?

EyePoint Pharmaceuticals' stock was trading at $10.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EYPT shares have decreased by 7.3% and is now trading at $9.73.
View which stocks have been most impacted by COVID-19

When did EyePoint Pharmaceuticals' stock split? How did EyePoint Pharmaceuticals' stock split work?

Shares of EyePoint Pharmaceuticals reverse split on the morning of Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 8th 2020. An investor that had 100 shares of EyePoint Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for EYPT?

4 analysts have issued 1-year target prices for EyePoint Pharmaceuticals' stock. Their forecasts range from $8.50 to $25.00. On average, they anticipate EyePoint Pharmaceuticals' share price to reach $17.63 in the next year. This suggests a possible upside of 81.1% from the stock's current price.
View analysts' price targets for EyePoint Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are EyePoint Pharmaceuticals' key executives?

EyePoint Pharmaceuticals' management team includes the following people:
  • Ms. Nancy S. Lurker, Pres, CEO & Director (Age 64, Pay $736.41k)
  • Mr. George O. Elston, CFO & Head of Corp. Devel. (Age 56, Pay $489.15k)
  • Dr. Jay S. Duker, Chief Strategic Scientific Officer (Age 62, Pay $53k)
  • Dr. Dario A. Paggiarino, Sr. VP & Chief Medical Officer (Age 64, Pay $541.39k)
  • Mr. Said Saim, Chief Technology Officer (Age 63)
  • Mr. Ron I. Honig Esq., Chief Legal Officer & Company Sec.
  • Ms. Jennifer Leonard, Sr. VP of HR & IT
  • Dr. John Weet, Sr. VP of Regulatory
  • Mr. David Scott Jones, Sr. VP & Chief Commercial Officer (Age 54)
  • Dr. Anna Kluczewska, CEO of AION Diagnostics Ltd, Pres of AION Diagnostics Ltd and Director of AION Diagnostics Ltd

Who are some of EyePoint Pharmaceuticals' key competitors?

What other stocks do shareholders of EyePoint Pharmaceuticals own?

What is EyePoint Pharmaceuticals' stock symbol?

EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

Who are EyePoint Pharmaceuticals' major shareholders?

EyePoint Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (10.05%), RA Capital Management L.P. (4.35%), Suvretta Capital Management LLC (4.11%), Janus Henderson Group PLC (2.34%), Samsara BioCapital LLC (1.57%) and Acuta Capital Partners LLC (1.33%). Company insiders that own EyePoint Pharmaceuticals stock include George Elston and Nancy Lurker.
View institutional ownership trends for EyePoint Pharmaceuticals

Which institutional investors are selling EyePoint Pharmaceuticals stock?

EYPT stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC.
View insider buying and selling activity for EyePoint Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying EyePoint Pharmaceuticals stock?

EYPT stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., RA Capital Management L.P., Suvretta Capital Management LLC, Janus Henderson Group PLC, Samsara BioCapital LLC, Acuta Capital Partners LLC, Silverarc Capital Management LLC, and Altium Capital Management LP. Company insiders that have bought EyePoint Pharmaceuticals stock in the last two years include George Elston, and Nancy Lurker.
View insider buying and selling activity for EyePoint Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of EyePoint Pharmaceuticals?

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is EyePoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $9.73.

How much money does EyePoint Pharmaceuticals make?

EyePoint Pharmaceuticals has a market capitalization of $279.65 million and generates $34.44 million in revenue each year. The company earns $-45,390,000.00 in net income (profit) each year or ($3.47) on an earnings per share basis.

How many employees does EyePoint Pharmaceuticals have?

EyePoint Pharmaceuticals employs 98 workers across the globe.

What is EyePoint Pharmaceuticals' official website?

The official website for EyePoint Pharmaceuticals is

Where are EyePoint Pharmaceuticals' headquarters?

EyePoint Pharmaceuticals is headquartered at 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472.

How can I contact EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.